SynthesisPloS one2026
Performance, physiology, and determinants of success in IRONMAN® 70.3: A systematic review.
Synthesis in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIRONMAN® 70.3 events represent a rapidly expanding endurance discipline characterized by distinct physiological demands, performance determinants, and race-specific risk profiles. Despite their global popularity, no systematic review has synthesized evidence exclusively focused on this distance.
objectiveTo consolidate current knowledge on performance predictors, physiological responses, training characteristics, nutritional strategies, environmental influences, and medical considerations in IRONMAN® 70.3 triathletes, and to identify gaps requiring further investigation.
methodsA systematic search of PubMed, Scopus, SciELO, EBSCO and Google Scholar was conducted up to 25th November 2025. Search terms were developed according to PRISMA guidelines and included variations of 'Ironman 70.3', 'half triathlon' and 'middle-distance triathlon'. Eligible studies reporting physiological, anthropometric, nutritional, environmental, medical, or performance-related outcomes specific to IRONMAN® 70.3. Risk of bias was assessed using the Newcastle-Ottawa Scale, the Cochrane RoB tool, and the NIH Quality Assessment Tool, according to study design.
resultsA total of 86 studies were included, predominantly observational in design, with sample sizes ranging from 1 to 852,721 participants, mostly trained male triathletes aged 25-39 years. Participation has increased across age groups, with pronounced growth among female and masters triathletes. Peak performance in professional male triathletes is reached at approximately age 28, and in female triathletes at age 32. Across large datasets, cycling appeared to be the strongest predictor of overall race time, accounting for the largest proportion of performance variance. Physiologically, competition was associated with transient reductions in immune function, reversible muscle damage, and shifts in hydration and electrolyte balance, while higher intracellular water and efficient fat oxidation were associated with better outcomes.
conclusionsEvidence specific to IRONMAN® 70.3 is limited by small sample sizes, heterogeneous designs, male-dominated cohorts, and insufficient sex-specific analyses. Future research should distinguish recreational from elite triathletes, incorporate balanced sex representation, and apply standardized physiological and environmental monitoring to refine targeted recommendations for performance, health, and safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.